MedTrace Logo

Long-term Use of CCB and Breast Cancer Risk

NCT05972785 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 68500

Last updated 2024-08-21

No results posted yet for this study

Summary

The goal of this retrospective observational study is to examine whether long-term calcium channel blocker (CCB) use is associated with the development of breast cancer amongst women enrolled in three longitudinal cohort studies in Australia and the Netherlands . The main questions it aims to answer are:

* Is long-term CCB use associated with the development of breast cancer amongst women enrolled in three longitudinal cohort studies in Australia and the Netherlands and what is the dose-response nature of this association.
* Does differences in the association between calcium channel blocker use and the development of breast cancer exist between Australian and Dutch women.

The investigators will utilise data from the Australian Longitudinal Study on Women's Health (ALSWH) , 45 and Up Study and Rotterdam study.

Conditions

Interventions

DRUG

Calcium channel blocker

Drugs with ATC code C08 will be categorised as calcium channel blockers.

DRUG

Beta blocker

Drugs with ATC code C07 will be categorised as beta-blockers.

DRUG

Diuretic

Drugs with ATC code C03 will be categorised as diuretics.

DRUG

RAS

Drugs with ATC code C09 will be categorised as RAS (agents acting on the renin angiotensin system).

DRUG

Other AHT

Drugs with ATC code C02 will be categorised as other antihypertensives.

DRUG

None AHT

None AHT

Sponsors & Collaborators

  • Curtin University

    lead OTHER

Eligibility

Min Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2025-06-30
Completion
2025-12-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05972785 on ClinicalTrials.gov